Moderna : Une base de comparaison délicate pour les futurs entrants
>De la place pour tout le monde, mais l’ARNm montre une efficacité supérieure - Vendredi a été une journée riche dans l’actualité du vaccin contre la COVID-19. Nous avons eu les résultats cliniques de deux phases 3, Novavax et JnJ ainsi que l’approbation du 3eme vaccin contre la COVID-19 en Europe venant d’AZN.Alors que nous aurions pu initialement penser que cette actualité pouvait impacter les premiers entrants, nous croyons qu’elle a renforcé notre call sur la...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.